Skip to main content

Idexx Laboratories Inc. Value Stock - Dividend - Research Selection

Idexx

ISIN: US45168D1046 , WKN: 888210

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow

2026-08-14
2026-08-14. The following slide deck was published by IDEXX Laboratories, Inc.

Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

2026-08-13
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...

IDEXX (IDXX) Q2 2026 Earnings Call Transcript

2026-08-11
Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

2026-08-11
WESTBROOK, Maine, August 11, 2026--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

2026-08-11
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.

IDEXX Laboratories: Worth The Premium

2026-08-08
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

2026-08-06
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

2026-08-05
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.

Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670

2026-08-05
Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.

IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary

2026-08-04
Moby summary of IDEXX Laboratories, Inc.'s Q2 2026 earnings call